{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carfilzomib&page=10", "query": { "intervention": "carfilzomib", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 193, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carfilzomib&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carfilzomib&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T10:30:15.296Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03432741", "title": "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Adenocarcinoma", "Metastatic Breast Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Hodgkin Lymphoma", "Recurrent Mycosis Fungoides", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Breast Carcinoma", "Refractory Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Belinostat", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Fludeoxyglucose F-18", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2018-03-27", "completion_date": "2022-10-03", "has_results": false, "last_update_posted_date": "2025-05-26", "last_synced_at": "2026-10-19T10:30:15.296Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03432741" }, { "nct_id": "NCT02047253", "title": "Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Acyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "MALE", "summary": "19 Years and older · Male only" }, "enrollment_count": 28, "start_date": "2014-04", "completion_date": "2017-07-14", "has_results": true, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-10-19T10:30:15.296Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Macon, Georgia • New Orleans, Louisiana", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Macon", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02047253" }, { "nct_id": "NCT01863550", "title": "Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1087, "start_date": "2013-12-06", "completion_date": "2034-02-05", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-19T10:30:15.296Z", "location_count": 909, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Hot Springs, Arkansas + 551 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01863550" }, { "nct_id": "NCT01276717", "title": "Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Drug: Carfilzomib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2011-01", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-10-19T10:30:15.296Z", "location_count": 2, "location_summary": "Rochester, New York • Richmond, Virginia", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01276717" }, { "nct_id": "NCT00530816", "title": "Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2007-09", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2017-05-02", "last_synced_at": "2026-10-19T10:30:15.296Z", "location_count": 26, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Laguna Hills, California + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tamarac", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00530816" }, { "nct_id": "NCT00884312", "title": "A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Solid Tumors" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2009-04-09", "completion_date": "2017-05-17", "has_results": true, "last_update_posted_date": "2018-05-14", "last_synced_at": "2026-10-19T10:30:15.296Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00884312" }, { "nct_id": "NCT01775553", "title": "Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapse Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ajai Chari", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2013-09", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-06-21", "last_synced_at": "2026-10-19T10:30:15.296Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01775553" }, { "nct_id": "NCT06232707", "title": "A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Alnuctamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-05-03", "completion_date": "2030-09-21", "has_results": false, "last_update_posted_date": "2024-05-31", "last_synced_at": "2026-10-19T10:30:15.296Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06232707" }, { "nct_id": "NCT01816971", "title": "Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "carfilzomib", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2013-01", "completion_date": "2026-03-30", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-10-19T10:30:15.296Z", "location_count": 4, "location_summary": "Chicago, Illinois • Boston, Massachusetts • St Louis, Missouri + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01816971" }, { "nct_id": "NCT07391657", "title": "A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "AZD0120", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 508, "start_date": "2026-02-23", "completion_date": "2030-07-29", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-19T10:30:15.296Z", "location_count": 48, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07391657" } ] }